TREATMENT OF REFRACTORY T-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA WITH PURINE NUCLEOSIDE ANALOGS

被引：15

作者：

WITZIG, TE

WEITZ, JJ

LUNDBERG, JH

TEFFERI, A

机构：

[1] Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN

[2] The St Cloud Clinic of Internal Medicine, St Cloud, Minnesota

[3] The Fond du Lac Clinic, Fond Du Lac, Wisconsin

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 14卷 / 1-2期

关键词：

T-CHRONIC LYMPHOCYTIC LEUKEMIA; FLUDARABINE;

D O I：

10.3109/10428199409049659

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for > 15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxyadenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.

引用

页码：137 / 139

页数：3

共 16 条

[1]

Phyliky R., Li C.-Y., Yam L., T-cell chronic lymphocytic leukemia with morphologic and immunologic characteristics of cytotoxic/suppressor phenotype, Mayo Clin. Proc, 58, pp. 709-720, (1983)

[2]

Matutes E., Brito B.V., Swansbury J., Ellis J., Morilla R., Dearden C., Sempere A., Catovsky D., Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia, Blood, 78, pp. 3269-3274, (1991)

[3]

Witzig T., Phyliky R., Li C.-Y., Homburger H., Dewald G., Handwerger B., T-cell chronic lymphocytic leukemia with a helper/inducer membrane phenotype: a distinct clinicopathologic subtype with a poor prognosis, Am. J. Hematol., 21, pp. 139-155, (1986)

[4]

Keating M.J., Kantarjian H., Talpaz M., Redman J., McCredie K.B., Fludarabine therapy in chronic lymphocytic leukemia (CLL), Nouv. Rev. Fr. Hematol., 30, pp. 461-466, (1988)

[5]

Piro L.D., Carrera C.J., Beutler B., Carson D.A., 2-Chloro-deoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia, Blood, 72, pp. 1069-1073, (1988)

[6]

Kantarjian Childs H.M.C., O'Brien S., Huh Y., Beran M., Schachner J., Koller C., Keating M.J., Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocyte leukemia and the prolympho-cytoid variant of chronic lymphocytic leukemia, Am. J. Med., 90, pp. 223-228, (1991)

[7]

Dearden C., Matutes E., Catovsky D., Deoxycoformycin in the treatment of mature T-cell leukaemias, Br. J. Cancer, 64, pp. 903-906, (1991)

[8]

Dohner H., Ho A., Thaler J., Stryckmans P., Sonneveld P., de Witte T., Lechner K., Lauria F., Bodewadt-Radzun S., Witt B., Hunstein W., Zittoun R., Pentostatin in prolymphocyte leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group, J. Nail. Cancer Inst., 85, pp. 658-662, (1993)

[9]

Brito-Babapulle F., Huang D., Lavender P., Gallon D., Catovsky D., Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deox-ycoformycin, Eur. J. Haematol., 40, pp. 185-187, (1988)

[10]

el Agnaf M.R., Ennis K.E., Morris T.C., Robertson J.H., Markey G., Alexander H.D., Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia, Br. J. Haematol., 63, pp. 93-104, (1986)

← 1 2 →